Description

Advanced Product Description: Ipamorelin — Selective GH Secretagogue for Precision Muscle & Recovery Research

Ipamorelin is one of the most advanced and selectively targeted Growth Hormone Secretagogues (GHS) available for scientific research. Engineered to stimulate endogenous growth hormone (GH) release without significantly influencing cortisol or prolactin, Ipamorelin delivers a “clean,” physiologic GH response—making it an ideal candidate for studies focused on muscle growth, metabolic enhancement, tissue repair, and aging.

Unlike earlier GHS peptides that triggered broad hormonal cascades, Ipamorelin offers a refined pathway: strong GH release with minimal off-target activity. This unique profile has made it one of the most widely investigated peptides for long-term metabolic and regenerative research.

Key Research Highlights of Ipamorelin

• Stimulates GH & IGF-1 Release – Promotes natural GH pulses without elevating stress hormones.

• Supports Lean Muscle Research – Often explored for anabolic pathways tied to GH → IGF-1 activation.

• Enhances Fat Metabolism – GH-driven lipolysis may support body composition studies.

• Improves Sleep & Recovery – Early observations point to deeper rest and accelerated repair.

• Highly Selective & Well-Tolerated – Much lower impact on ACTH, cortisol, and prolactin than earlier GHS peptides.

Ipamorelin is commonly administered via subcutaneous injection in research settings investigating metabolism, muscle physiology, recovery, and age-related decline.

For laboratory research only. Not for human or animal consumption.

Scientific Overview of Ipamorelin

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) classified as a selective Growth Hormone Secretagogue (GHS). It targets ghrelin receptors (GHSR-1a) within the pituitary and hypothalamus, initiating a controlled, pulse-based release of endogenous GH.

This tightly focused receptor activity distinguishes Ipamorelin from earlier compounds such as GHRP-6, GHRP-2, and Hexarelin, providing a more refined GH-elevating tool with reduced hormonal interference.

Mechanism of Action

Ipamorelin binds directly to ghrelin receptors, triggering natural GH secretion in a physiologic, pulsatile pattern—mirroring the body’s own endocrine rhythm. This process stimulates downstream IGF-1 production, which supports:

• Tissue repair and regeneration

• Muscle protein synthesis

• Metabolic balance

• Cellular growth and recovery

A defining advantage is its minimal influence on ACTH, cortisol, and prolactin, helping maintain a stable hormonal environment during extended research timelines.

Primary Research Applications

Muscle Growth & Recovery

• Activates GH → IGF-1 pathway to support muscle repair

• May enhance recovery from training stress or injury models

• Often evaluated for anabolic potential and tissue regeneration

Metabolic & Body Composition Studies

• Supports GH-driven lipolysis and fat mobilization

• May influence nutrient partitioning and lean mass retention

Aging & Regenerative Research

• Investigated for preserving bone mineral density, joint health, and connective tissue

• May influence circadian GH rhythms that support sleep quality and nighttime recovery

Pharmacokinetics

• Route: Subcutaneous injection

• Half-Life: ~2 hours (rapid onset)

• GH Pulse: Typically observed within 30 minutes

• IGF-1 Response: Increases with repeated administration over time

• Research Protocols: Short-acting profile often leads to multiple daily administrations in investigative settings

Structure & Molecular Properties

• Sequence: H-Aib-His-D-2-Nal-D-Phe-Lys-NH₂

• Formula: C₃₈H₄₉N₉O₅

• Molecular Weight: 711.9 g/mol

• CAS: 170851-70-4

Ipamorelin is engineered with high receptor selectivity, helping reduce unwanted side effects associated with earlier GHS molecules.

Safety Profile

Preclinical and investigational findings indicate Ipamorelin is generally well-tolerated, with a cleaner endocrine footprint than first-generation GHS peptides.

Commonly reported research-level effects include:

• Mild injection site irritation

• Temporary flushing or headache

• Minor, transient fluid shifts related to GH/IGF-1 modulation

Ipamorelin does not meaningfully elevate cortisol, prolactin, or ACTH at standard research exposures, contributing to its reputation as a stable and predictable GH secretagogue.

Regulatory Status

Ipamorelin is designated strictly for research and investigational use.

It is not FDA-approved for medical treatment or human/veterinary administration.

Current studies continue to explore its role in:

• Muscle physiology

• Metabolic modulation

• Aging & regenerative biology

• Endocrine system support